Rebecca Simpson, PhD, The University of Sydney, Sydney, Australia, provides an overview of an analysis of immune cells and related pathological responses in patients with stage III melanoma receiving ipilimumab and nivolumab in the Phase II OpACIN-neo trial (NCT02977052). Pre- and post-treatment peripheral blood mononuclear cells (PBMCs) were analyzed, which enabled the identification of differences in immune cells during treatment. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.